Please login to the form below

Not currently logged in
Email:
Password:

axi-cel

This page shows the latest axi-cel news and features for those working in and with pharma, biotech and healthcare.

New trial results suggest CAR-T effects are durable in lymphoma

New trial results suggest CAR-T effects are durable in lymphoma

Yescarta (axicabtagene ciloleucel or axi-cel) which was approved for that indication the previous October and made $40m in the first quarter, ahead of the $16m predicted by analysts. ... Celgene and Juno are hoping to crash the party soon with their

Latest news

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    At a stroke, Gilead becomes a front-runner in the race to bring the first CAR-T to market with Novartis, claiming Kite's late-stage candidate axicabtagene ciloleucel (axi-cel ... Kite also has a pipeline of other CAR-T therapies following behind axi-cel,

  • Kite starts EU trial of lead CAR-T therapy Kite starts EU trial of lead CAR-T therapy

    Kite Pharma has treated its first European patient with axicabtagene ciloleucel (KTE-C19 or axi-cel), its CAR-T therapy for B-cell lymphomas. ... The start of the trial comes after Kite has already filed for approval of axi-cel in the EU based on the

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Headline. $m. Kite (US). Gilead (US). Company acquisition. CAR-T technology with lead product ‘axi-cel’ under priority review at the FDA for treatment of refractory aggressive NHL.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics